Monoclonal antibody ch14.18 interleukin-2 fusion protein

Drug Profile

Monoclonal antibody ch14.18 interleukin-2 fusion protein

Alternative Names: Anti-ganglioside-GD2-antibody-interleukin-2-fusion-protein; APN 301; ch14.18-IL2; EMD 273063; hu14.18-IL2

Latest Information Update: 24 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lexigen Pharmaceuticals
  • Developer Apeiron Biologics; Merck KGaA; University of Wisconsin-Madison
  • Class Antineoplastics; Immunoglobulin fusion proteins; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma; Neuroblastoma

Most Recent Events

  • 11 Jul 2017 The University of Wisconsin plans a phase I trial for Neuroblastoma (In combination with natural killer cells, In infants, In children, In adolescents, In adults) in USA in September 2017 (NCT03209869)
  • 24 Sep 2015 Phase-II development for Malignant melanoma is ongoing in USA
  • 24 Sep 2015 Phase-II development for Neuroblastoma is ongoing in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top